Pharmaceutical interventions performed in COVID-19 patients treated with lopinavir/ritonavir combination, hydroxychloroquine or azithromycin and characterisation of the associated medication-related problems, University Hospital of Strasbourg, France
| Lopinavir/ritonavir | Hydroxychloroquine | Azithromycin | ||||||||||
| PIs* implemented | PIs* not implemented | Outcome unknown | Total | PIs* implemented | PIs* not implemented | Outcome unknown | Total | PIs* implemented | PIs* not implemented | Outcome unknown | Total | |
| Medication-related problems | ||||||||||||
| Non-conforming treatment duration | 17 | 2 | 19 | 6 | 1 | 1 | 8 | 4 | 1 | 5 | ||
| Incorrect dosage | 1 | 1 | 1 | 3 | 4 | 1 | 1 | |||||
| Drug interaction with: | 1 | 1 | 11 | 2 | 13† | |||||||
| Azithromycin | 1 | 1 | 1 | 2 | 3 | |||||||
| Erythromycin | 2 | 2 | ||||||||||
| Rovamycin | 1 | 1 | ||||||||||
| Haloperidol | 1 | 1 | ||||||||||
| Tiapride | 1 | 1 | ||||||||||
| Cyamemazine | 1 | 1 | ||||||||||
| Hydroxyzine | 4 | 4 | ||||||||||
| Non-optimal drug intake plan | 1 | 1 | ||||||||||
| Hydro-electrolytic disorders | 5 | 5 | ||||||||||
| Error related to computerisation | 1 | 1 | ||||||||||
| Total number of PIs | 21 | 32 | 6 | |||||||||
| Outcome of interventions (% of acceptance) | 90.5% | 78.1% | 66.7% | |||||||||
*PIs, pharmaceutical interventions.
†No ECG carried out to assess the QT interval before the PIs were performed.
ECG, electrocardiogram.